Dr. Morris on the Role of Immunotherapy in Metastatic CRC

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Van K. Morris, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of immunotherapy in metastatic colorectal cancer (CRC).

Immunotherapy has been an exciting addition to the armamentarium of metastatic CRC in the past few years, explains Morris.

However, only approximately 3% to 5% of all patients with metastatic CRC have microsatellite instability–high disease that is amenable to immunotherapy, says Morris. These patients can have favorable long-term outcomes with immunotherapy.

Translating these outcomes to patients with metastatic CRC who have microsatellite stable disease is an area of active research, concludes Morris.

Related Videos
Roger Li, MD, of Moffitt Cancer Center
Michael Deininger, MD, PhD
Shubham Pant, MD, MBBS
Kedar Kirtane, MD
Mazyar Shadman, MD, MPH
Allison Winter, MD, Department of Hematology and Medical Oncology, Cleveland Clinic
Malcolm Mattes, MD, associate professor, Section of Radiation Oncology, Rutgers Robert Wood Johnson Medical School; radiation oncologist, Rutgers Cancer Institute of New Jersey
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology